Zoledronic Acid

• Description :

  Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects[1].

• CAS Number :

  [118072-93-8]

• Product Name Alternative :

  Zoledronate; CGP 42446; CGP42446A; ZOL 446

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Apoptosis; Autophagy; Bacterial

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Apoptosis; Autophagy

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/zoledronic-acid.html

• Purity :

  99.94

• Solubility :

  H2O : 4.17 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  OC(P(O)(O)=O)(P(O)(O)=O)CN1C=CN=C1

• Molecular Formula :

  C5H10N2O7P2

• Molecular Weight :

  272.09

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Lianwei Wang, et al. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review. BMC Cancer. 2020; 20: 1059.|[2]Hyung Joon Kim, et al. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis. Int J Mol Sci. 2019 Mar; 20 (6) : 1467.|[3]Xiao-Lin Huang, et al. Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways. Int J Mol Med. 2019 Aug;44 (2) :582-592.|[4]XIN HUANG, et al. Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro. Mol Med Rep. 2016 Jan; 13 (1) : 613-622.|[5]Samantha Pozzi, et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009 Sep 15;15 (18) :5829-39.|[6]Shea GKH, et al. Oral Zoledronic acid bisphosphonate for the treatment of chronic low back pain with associated Modic changes: A pilot randomized controlled trial. J Orthop Res. 2022 Feb 23.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Citation 01 :

  ACS Appl Mater Interfaces. 2025 Jun 25;17 (25) :36315-36333.|ACS Nano. 2023 Jul 25;17 (14) :13917-13937.|Appl Biochem Biotechnol. 2024 Oct;196 (10) :7362-7374.|bioRxiv. 2025 March 11.|Bone. 2024 Aug 3:117222.|Commun Biol. 2024 Nov 9;7 (1) :1476.|Eur J Med Chem. 2024 Dec 5:279:116842.|Int Immunopharmacol. 2022 Sep:110:109030.|J Dent Sci. 2024 May 4.|JCI Insight. 2025 Jan 30:e184468.|Med Oncol. 2023 Apr 10;40 (5) :141.|Nat Commun. 2024 Mar 21;15 (1) :2529.|Natl Sci Rev. 2025 Jun 27;12 (8) :nwaf256.|Oxid Med Cell Longev. 2021 Mar 30:2021:6661534.|SSRN. 2025 Sep 23.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Dis Markers. 2021 Oct 15;2021:5838582.|Gut Microbes. 2023 Dec;15 (2) :2249143.|Int J Parasitol Drugs Drug Resist. 2025 Aug 6:29:100607.